EXEL vs TECH: stock comparison and AI forecast
Exelixis, Inc. (EXEL) and Bio-Techne Corp (TECH) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
EXEL Exelixis, Inc.
- Price
- $69.57 +50.6% · 6M
- Market Cap
- $16.98B
- P/E Ratio
- 25.0x
- Size
- large-cap
- AI Forecast
TECH Bio-Techne Corp
- Price
- $72.78 +43.0% · 6M
- Market Cap
- $11.43B
- P/E Ratio
- 66.2x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- EXEL is 1.5 times larger than TECH by market capitalization ($16.98B against $11.43B).
- EXEL trades at 25.0 times trailing earnings, TECH at 66.2 times.
- Over the last six months EXEL returned +50.6% and TECH +43.0%.
- EXEL turns 33.7% of its revenue into net income, against 14.0% for TECH.
- EXEL carries 0.37 times debt per unit of equity, against 0.22 times for TECH.
- TECH yields 0.44% in dividends; EXEL pays none.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | EXEL | TECH |
|---|---|---|
| Market Cap | $16.98B | $11.43B |
| P/E Ratio | 25.03x | 66.16x |
| P/B Ratio | 9.26x | 5.28x |
| Dividend Yield | – | 0.44% |
| EPS | $2.78 | $1.10 |
| Book Value/Share | $7.52 | $13.79 |
| Revenue/Share | $9.61 | $7.82 |
| FCF/Share | $3.92 | $1.96 |
Profitability & Margins
| Metric | EXEL | TECH |
|---|---|---|
| ROE | 42.7% | 7.9% |
| ROA | 31.1% | 6.5% |
| ROIC | 41.5% | 10.6% |
| Gross Margin | 96.4% | 65.8% |
| Operating Margin | 37.6% | 19.6% |
| Net Margin | 33.7% | 14.0% |
| EBT Margin | 37.6% | 18.5% |
| Tax Rate | 18.2% | 24.4% |
Financial Health
| Metric | EXEL | TECH |
|---|---|---|
| Current Ratio | 3.21x | 2.28x |
| Quick Ratio | 3.14x | 1.74x |
| D/E Ratio | 0.37x | 0.22x |
| Financial Leverage | 1.37x | 1.22x |
| Interest Coverage | 6.4x | 13.8x |
| Working Capital | $910M | $464M |
Cash Flow
| Metric | EXEL | TECH |
|---|---|---|
| Operating Cash Flow | $884M | $338M |
| Free Cash Flow | $957M | $308M |
| Capital Spending | $73M | -$29M |
| OCF Growth YoY | 26.3% | 34.4% |
| FCF Growth YoY | 42.5% | 37.5% |
| FCF/Sales | 40.8% | 25.1% |
| CapEx/Sales | 3.1% | 2.4% |
Operational Efficiency
| Metric | EXEL | TECH |
|---|---|---|
| Asset Turnover | 0.93x | 0.47x |
| Receivables Turnover | 7.1x | 6.0x |
| Inventory Turnover | 2.8x | 2.1x |
| Fixed Assets Turnover | 26.9x | 5.4x |
| Days Sales Outstanding | 51 days | 60 days |
| Days Inventory | 130 days | 172 days |
| Payables Period | 134 days | 27 days |
| Cash Conversion Cycle | 47 days | 205 days |
Income Statement
| Metric | EXEL | TECH |
|---|---|---|
| Total Revenue | $2.35B | $1.23B |
| Operating Income | $872M | $241M |
| Net Income | $783M | $172M |
| R&D Expense | $825M | $97M |
| SG&A Expense | $519M | $470M |
| Cost of Goods Sold | $84M | $421M |
Dividend & Shareholder Information
| Metric | EXEL | TECH |
|---|---|---|
| Dividends Per Share | – | $0.32 |
| Payout Ratio | – | 29.1% |
| Shares Outstanding | 244M | 157M |
| Net Income Growth | 50.1% | 120.5% |
| EPS Growth | 58.0% | 124.5% |
EXEL vs TECH: stock comparison and AI forecast
Which is bigger, EXEL or TECH?
EXEL is 1.5 times larger than TECH by market capitalization ($16.98B against $11.43B).
Which is cheaper on earnings, EXEL or TECH?
EXEL trades at 25.0 times trailing earnings, TECH at 66.2 times.
Which stock performed better over the last six months, EXEL or TECH?
Over the last six months EXEL returned +50.6% and TECH +43.0%.
Which one does Intratio's AI model rank higher, EXEL or TECH?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.